biote Corp. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing condensed consolidated financial statements and updated share counts as of November 4, 2026.

Key Highlights

  • Total assets: $101,696 thousand as of September 30, 2026, down from $107,613 thousand at December 31, 2025, according to the filing.
  • Cash and cash equivalents: $8,851 thousand at September 30, 2026, compared with $24,123 thousand at December 31, 2025, the company disclosed.
  • Term loan: The current portion stood at $3,125 thousand and the net-of-current portion at $116,947 thousand as of September 30, 2026, per the filing.
  • Share repurchase liabilities: Reduced to zero at September 30, 2026, from $18,500 thousand at December 31, 2025, the registrant reported.
  • Class A common stock outstanding: 27,040,089 shares as of September 30, 2026, with 28,627,589 shares outstanding as of November 4, 2026, according to the filing.
  • Accrued expenses: Rose to $14,698 thousand from $9,806 thousand at year-end 2025, the company disclosed.

biote Corp. Balance Sheet and Capital Structure at September 30, 2026

biote Corp. (NASDAQ:BTMD), a Delaware-incorporated company headquartered in Irving, Texas, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, the company operates in the bioidentical hormone pellet therapy space and offers the Biote Method to practitioners and clinics, as well as dietary supplements. The filing notes among its risk factors the company's reliance on third-party pellet suppliers, a voluntary product recall of certain hormone pellets, and the need to grow acceptance of its dietary supplements among clinics, practitioners, and their patients.

The condensed consolidated balance sheet shows total assets of $101,696 thousand at September 30, 2026, a decrease from $107,613 thousand at December 31, 2025, the registrant reported. Cash and cash equivalents fell to $8,851 thousand from $24,123 thousand over the same period. Inventory, net declined to $17,765 thousand from $19,064 thousand, while accounts receivable, net increased slightly to $7,285 thousand from $6,868 thousand, according to the filing.

On the liabilities side, the filing discloses that total liabilities increased modestly to $159,294 thousand from $158,010 thousand. The term loan net of current portion increased to $116,947 thousand from $95,782 thousand, while the revolving loans balance was reduced to zero from $5,000 thousand. The share repurchase liabilities line, which carried a balance of $18,500 thousand at December 31, 2025, was reported at zero as of September 30, 2026. Earnout liabilities current of $1,750 thousand appeared on the September 30, 2026 balance sheet, compared with zero at the prior year-end, the company disclosed. The registrant is classified as an accelerated filer, a smaller reporting company, and an emerging growth company, as indicated on the cover page of the filing.

What Was Disclosed

biote Corp. disclosed its unaudited condensed consolidated balance sheet as of September 30, 2026, alongside comparative figures from December 31, 2025. The filing covers changes in cash, inventory, debt structure, share counts, and accrued liabilities for the quarterly period, and includes forward-looking statements the company cautions should not be relied upon as representations of future results.